Andrea Wang-Gillam, MD, PhD of Washington University School of Medicine @WUSTLmed answers if the phase I study of defactinib combined…
Browsing: Pancreatic
Andrea Wang-Gillam, MD, PhD of Washington University School of Medicine @WUSTLmed discusses the phase I study of defactinib combined with…
Earn CME: https://www.naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment…
Earn CME: https://www.naccme.com/program/19-gdu… In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment…
Earn CME: https://naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment…
Earn CME: https://naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment…
Pancreatic cancer has one of the worst survival rates among cancers. Patients can expect as low as a 9% chance to…
GRACE is very excited to bring to you more videos from our program, Supportive Care in Cancer Treatment.Arjun Gupta, MD…
Source: https://www.spreaker.com/user/cancergrace/supportive-care-6-pert Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video,…
World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of…
– Data from pivotal study demonstrate safety and efficacy regardless of prior gastrectomy in previously treated patients with metastatic gastric…
Finding May Explain Why Promising Drugs Work – And When They Won’t   CHARLOTTESVILLE, Va., Sept. 26, 2019 – A…
TORONTO, CANADA / ACCESSWIRE / September 24, 2019 / Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, today…
Shauna Campbell, MD of Cleveland Clinic shares three nomograms that were presented on salvage radiotherapy. _____ The integration of prostate-specific…
Shauna Campbell, MD of Cleveland Clinic answers a question received from colleagues: how does it differ from previously published nomograms?…
New discovery opens new potentially effective approaches to utilize checkpoint inhibitors for treatment of pancreatic cancer and other types of…
Afsaneh Barzi, MD of Norris Cancer Center provides insight on the still unanswered questions in the POLO study.
Afsaneh Barzi, MD of Norris Cancer Center explains the phase III POLO trial, a maintenance treatment following first-line platinum-based chemotherapy…
Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 is the leading drug in a phase 1b clinical trial in late…
Jack Stewart, CSO of Soricimed Biopharma discusses SOR-C13, a selective inhibitor of TRPV6, binds with affinity and disrupts how TRPV6…
Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 potentially shows promise in ovarian, metastatic prostate and pancreatic cancer.
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center shares the important role biomarkers have in the treatment of pancreatic…
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center describes the outcomes from the POLO study in pancreatic cancer and…
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center explains the potential of the POLO trial maintenance with olaparib in…
Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope discusses details from APACT study, a phase…
Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope shares statistics and data on strategies that…
Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope provides outcomes on the POLO Trial with…
Thomas A. Abrams, Senior Physician and Assistant Medical Professor at Harvard Medical School provides results about the APACT Study. APACT…
Dr. Thomas A. Abrams, Senior Physician and Assistant Professor of Medicine at Harvard Medical School discusses whether the POLO Trial…
Michael Hall, MD Of Fox Chase Cancer Center Discusses POLO Trial: PFS Increased With Olaparib As Maintenance Therapy For BRCA+…
Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Personalized Medicine In Pancreas Cancer. At MOASC…
Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Know Your Tumor Initiative. At MOASC Oncology…
Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Evolution Of Pancreatic Cancer Treatment. At MOASC…
Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Elaborating On Pancreas Cancer. At MOASC Oncology…
Andrew Hendifar, M.D. Medical Director, Pancreatic Cancer Cedars-Sinai Medical Center, Discusses Personalized Therapy For Pancreas Cancer: Have We Arrived? Dr.…
John Strickler, M.D. Assistant Professor Of Medicine At Duke Cancer Institute, Discusses Comprehensive Genomic Profiling Of Pancreatic Cancer. At The…
Bassel El-Rayes, M.D. Professor & Vice Chair For Clinical Research, Department Of Hematology & Medical Oncology Emory University School Of…
Bassel El-Rayes, M.D. Professor & Vice Chair For Clinical Research, Department Of Hematology & Medical Oncology Emory University School Of…
Zev Wainberg, M.D. Co-Director UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Hematology Oncology David Geffen School Of Medicine At…
Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann…
Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann…
Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann…
Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann…
Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann…
Rachna Shroff, MD Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer…
Yung Lyou, MD, UC Irvine Health, talks about Keynote 61 Trial | See if Pembrolizumab Can be Moved to the…
Yung Lyou, MD, UC Irvine Health, talks about Weighing Judgment Before Giving Ramucirumab | Ramucirumab is Viable Choice After REACH-2…
Yung Lyou, MD, UC Irvine Health, talks about Selecting Patients for Adjuvant Pancreatic Treatment | Determine Who Has Better Performance…
Yung Lyou, MD, UC Irvine Health, talks PRODIGE 24 Showed FOLFIRINOX has Benefits | FOLFIRINOX was Compared to Single-Agent Gemcitabine…
Richard Goldberg, MD, on preoperative chemotherapy in pancreatic cancer and whether the PREOPANC-1 has influenced the path of treatment